A Phase III, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib
in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who
Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint
Inhibitor 257305
A Phase I/II Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Na�ve or Received Incomplete BCG Treatment LEGEND STUDY
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative with Evident Efficacy in Patients with Muscle Invasive Bladder Cancer